JPMorgan Chase & Co. Trims Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

JPMorgan Chase & Co. trimmed its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 5.1% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 19,745 shares of the company’s stock after selling 1,062 shares during the period. JPMorgan Chase & Co.’s holdings in Enliven Therapeutics were worth $444,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Enliven Therapeutics by 2.9% in the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock valued at $44,452,000 after purchasing an additional 55,283 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Enliven Therapeutics in the fourth quarter valued at about $97,000. Intech Investment Management LLC purchased a new position in Enliven Therapeutics during the fourth quarter worth about $367,000. Swiss National Bank increased its position in shares of Enliven Therapeutics by 13.9% during the fourth quarter. Swiss National Bank now owns 41,873 shares of the company’s stock valued at $942,000 after acquiring an additional 5,100 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Enliven Therapeutics by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company’s stock valued at $5,892,000 after acquiring an additional 6,611 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the sale, the chief operating officer now owns 329,977 shares of the company’s stock, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $16.07, for a total value of $80,350.00. Following the completion of the transaction, the insider now owns 997,688 shares of the company’s stock, valued at $16,032,846.16. The trade was a 0.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,751 shares of company stock valued at $1,331,288 in the last 90 days. Company insiders own 29.20% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $19.85 on Friday. The stock has a market capitalization of $972.73 million, a price-to-earnings ratio of -10.45 and a beta of 1.03. The business has a 50-day moving average of $19.16 and a 200 day moving average of $22.47. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. Equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.